A
AbCellera Biologics Inc. (ABCL)
NMS – Real Time Price. Currency in USD
3.27
-0.08 (-2.39%)
At close: Mar 27, 2026, 4:00 PM EDT
3.26
-0.01 (-0.31%)
After-hours: Mar 27, 2026, 7:34 PM EDT
Get all premium features to the best stock analysis tool
NMS – Real Time Price. Currency in USD
3.27
-0.08 (-2.39%)
At close: Mar 27, 2026, 4:00 PM EDT
3.26
-0.01 (-0.31%)
After-hours: Mar 27, 2026, 7:34 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 11.32 | 6.05 | 10 | |
| Quick ratio | 11.23 | 5.63 | 10 | |
| Debt to Equity | 0.15 | 0.30 | 9.0 | |
| Debt to Assets | 0.11 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 485M | 38M | 29M | 75M | 75M |
| Gross Profit | N/A | 7M | -68M | 46M | 46M |
| Operating Income | 283M | -237M | -315M | -217M | -217M |
| Net Income | 159M | -146M | -163M | -146M | -146M |
| EBITDA | 316M | -206M | -218M | -188M | -188M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 34.13 | -4 | 5.5 |
| Next quarter | -56.71 | -28.33 | 1.0 |
| Current year | -60.21 | -31.97 | 1.0 |
| Next year | 23.92 | -1.75 | 5.5 |
| Weighted average score | 3.3 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 400.87 | 84.34 | 84.21 | 31.05 | 10 |
| Y/Y | 788.18 | 73.85 | 75 | -109.99 | 7.8 |
| 3y average | 14.75 | -64.48 | -66.29 | -68.75 | 2.8 |
| 5y average | 26.91 | -32.22 | -37.6 | 226.94 | 5.5 |
| Weighted average score | 6.5 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $155.0M significantly exceed its total debt $143.2M, ensuring strong financial flexibility
Total current assets $728.2M exceed Total current liabilities $64.3M, highlighting excellent liquidity
Debt-to-equity ratio (0.1) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$43.0M limits the company's ability to reinvest or pay down debt